GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nimotuzumab   Click here for help

GtoPdb Ligand ID: 7988

Synonyms: h-R3 | THERACIM® | Theraloc®
Approved drug
nimotuzumab is an approved drug (China, India, others (2014))
Compound class: Antibody
Comment: Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1].

Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar
References
1. Meteo de Acosta del Rio CM, Rodríguez RP, Frías EM. (2003)
Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use.
Patent number: US6506883. Assignee: Centro De Inmunologia Molecular. Priority date: 18/11/1994. Publication date: 14/01/2003.